Physician profile
Terrence L Jackson
NPI 1760484372
$12,281.18
in general payments reported to CMS, 2019-2025
37 companies · $3,396 in 2025
The $3,396 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $521 · 2021: $216 · 2022: $2,167 · 2023: $1,907 · 2024: $2,466 · 2025: $3,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,705 · Education: $64.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,704.65 |
| Education | $64.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,093.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,954.22 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,152.21 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $889.86 | 2019-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $592.98 | 2022-2025 | |
| Gilead Sciences, INC. | $521.58 | 2019-2025 | |
| Pfizer INC. | $471.76 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $467.04 | 2024-2025 | Voquezna |
| Celgene Corporation | $423.57 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $376.31 | 2023-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $350.62 | 2019-2023 | Rebyota |
| Aimmune Therapeutics, INC. | $306.07 | 2024-2025 | Zenpep, Vowst |
| Ardelyx, INC. | $290.79 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $280.55 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $254.14 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $235.16 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $230.00 | 2021-2023 | |
| Qol Medical, LLC | $215.37 | 2022-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $212.06 | 2019-2024 | Linzess |
| Enterra Medical, INC. | $185.69 | 2024-2025 | |
| Sirtex Medical INC | $158.76 | 2020 | |
| Merck Sharp & Dohme LLC | $141.99 | 2022-2024 | Dificid |
| Evoke Pharma, INC. | $80.76 | 2022-2025 | Gimoti |
| Amag Pharmaceuticals, INC. | $63.09 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $52.45 | 2024-2025 | Iqirvo |
| Amgen INC. | $51.57 | 2022-2023 | Avsola, Amjevita |
| Vivus LLC | $49.84 | 2024-2025 | Pancreaze, Qsymia |
| Shield Therapeutics INC | $43.86 | 2023 | Accrufer |
| Regeneron Healthcare Solutions, INC. | $26.49 | 2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $15.20 | 2023 | Terlivaz |
| Micro-Tech Endoscopy USA, INC. | $15.18 | 2024 | Button |
| Sandoz INC. | $15.06 | 2024 | Hyrimoz |
| Olympus America INC. | $14.53 | 2020 | |
| Boston Scientific Corporation | $13.64 | 2019 | |
| Ucb, INC. | $12.82 | 2019 | |
| Shire North American Group INC | $11.87 | 2019 | |
| Daiichi Sankyo INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.